Sandoz launches Pyzchiva autoinjector, first commercially available in Europe for ustekinumab biosimilars

Sandoz announced the European launch of its Pyzchiva  (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered by Samsung Bioepis, Pyzchiva is approved for the treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis for patients aged six years and older, weighing over 60 kg.  The autoinjector is now initially  available in Spain and will continue to roll out across Europe.

The Pyzchiva autoinjector supports a more comfortable self-administration experience  with accurate automatic dosing, less frequent injection pain , a compact design and flexible storage options offering the potential for improved adherence to patient treatment plans. The Pyzchiva autoinjector is a pre-filled pen delivered through the Molly platform of SHL Medical AG. It is available as a 90 mg in 1 mL autoinjector or a 45 mg in 0.5 mL autoinjector.

Christophe Delenta, President Europe, Sandoz, said: “Access to medicine does not end when it reaches the hands of the patient. The Pyzchiva autoinjector, with its thoughtful and advanced features, addresses the real-world needs of patients in managing chronic inflammatory diseases. This launch marks another important milestone as we strengthen our leadership in immunology biosimilars and reaffirm our commitment to pioneering access across Europe’s evolving healthcare landscape.”